Engaged Capital’s Aratana Therapeutics, Inc. PETX Stock Holding History

Engaged Capital’s Portfolio PETX Stock Details PETX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-2,417,149	Closed	-$8.7M	–	12
2019 Q1	$8.7M	Sell	2,417,149 -1,070,000	-31%	-$4.64M	1.22%	11
2018 Q4	$21.4M	Sell	3,487,149 -577,930	-14%	-$3.53M	3.96%	9
2018 Q3	$23.7M	Buy	4,065,079 +1,665,079	+69%	+$8.32M	3.33%	8
2018 Q2	$10.2M	Buy	2,400,000 +400,000	+20%	+$2.02M	1.28%	11
2018 Q1	$8.82M	Buy	+2,000,000	New	+$8.92M	1.2%	11

Other funds holding PETX

Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

WIC

Water Island Capital New York $896M AUM 107.59% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

AAM

Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OAC

OMERS Administration Corp Toronto, Ontario, Canada $15.6B AUM 24.73% 1-Year Est. Return

Engaged Capital's PETX Position: Q2 2019 in Review

Engaged Capital sold out of Aratana Therapeutics, Inc. (PETX) in Q2 2019, closing a stake of 2,417,149 shares — an estimated $8.7M sold.

Engaged Capital first reported a position in PETX in Q1 2018 and held it in 5 quarters. The position peaked at $23.7M in Q3 2018. 103 funds tracked by Wall St. Rank hold PETX as of Q2 2019.

Engaged Capital reported no remaining Aratana Therapeutics, Inc. position as of Q2 2019 after selling out during the quarter.
Engaged Capital sold 2,417,149 Aratana Therapeutics, Inc. shares in Q2 2019, an estimated $8.7M.
Engaged Capital first reported a position in Aratana Therapeutics, Inc. in Q1 2018 and held it in 5 quarters.
Engaged Capital's Aratana Therapeutics, Inc. position peaked at $23.7M in Q3 2018.
103 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q2 2019.

Based on Engaged Capital's 13F filing for Q2 2019, filed 14 Aug 2019.